Liarozole acts synergistically with 1α,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity

Endocrinology

Volumn 140, Issue 5, 1999, Pages 2071-2076

  Ly, Lan H ^a   Zhao, Xiao Yan ^a   Holloway, Leah ^a   Feldman, David ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIDIOL 1 MONOOXYGENASE; CALCITRIOL; CYTOCHROME P450; KETOCONAZOLE; LIAROZOLE FUMARATE;

ARTICLE; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG POTENTIATION; ENZYME REGULATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

EID: 0033324493     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.140.5.6698     Document Type: Article

References (33)

1. Vitamin D: Metabolism and action
2. Vitamin D: A modulator of cell proliferation and differentiation
3. Newly identified actions of the vitamin D endocrine system
4. Clinical counterpoint: Vitamin D: New actions, new analogs, new therapeutic potential
5. 3 receptors and actions in human prostate cancer cell lines
6. Human prostate cancer cells: Inhibition of proliferation by vitamin D analogs
7. 3 in seven human prostatic carcinoma cell lines
8. 3
9. 3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin
10. 3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1
11. 3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation
12. 3 on primary cultures of human prostatic cells
13. 3 (analogs) by cytochrome P450 enzyme inhibitors is compound- and cell-type specific
14. Ketoconazole and other imidazole derivatives as inhibitors of steroidogenesis
15. Experimental studies with liarozole (R 75 251): An antitumoral agent which inhibits retinoic acid breakdown
16. Phase I/II dose escalation study of liarozole in patients with stage D, hormone refractory carcinoma of the prostate
17. R 75251, a new inhibitor of steroid biosynthesis
18. Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo
19. 3 and dexamethasone on rat osteoblast-like primary cell cultures: Receptor occupancy and funtional expression patterns for three different bioresponses
20. 3 receptor gene expression and enhances hormone action
21. 3 receptors by vitamin D analogs in cultured mammalian cells
22. 3 receptor turnover by dense amino acid labeling: Changes during up-regulation by vitamin D metabolites
23. 3 in cultured mouse osteoblast-like cells-modulation by changes in receptor level
24. Regulation of vitamin D receptor abundance
25. 3 by intact rat osteogenic sarcoma cells
26. 3 receptor up-regulation in rat osteosarcoma cells
27. 3 in the human prostatic carcinoma cell line ALVA-31
28. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines
29. Modulation of all-trans retinoic acid pharmacokinetics by liarozole
30. Effect of retinoic acid on the proliferation and secretory activity of androgen-responsive prostatic carcinoma cells
31. 3 on prostatic epithelial cells
32. 3
33. 3 actions in LNCaP human prostate cancer cells are androgen-dependent